Effectiveness of the fixed-dose combination therapy with perindopril and amlodipine in coronary heart disease patients after coronary artery bypass graft surgery

Author:

Iskenderov B. G.1,Sisina O. N.1,Kameneva O. A.1

Affiliation:

1. Penza Institute of Post-diploma Medical Education

Abstract

Aim. To study the effectiveness of the fixed-dose combination therapy with perindopril and amlodipine (Prestance 5/5 mg/d) in coronary heart disease (CHD) patients after coronary artery bypass graft (CABG) surgery. Material and methods. The clinical trial included 65 patients (37 men, 28 women aged 45-68 years; mean age 56,3±3,5 years) after CABG. All patients were randomised into two groups: the control group (CG; n=35) and the main group (MG; n=30). Both groups received antiplatelet agents and statins, while the MG patients additionally received Prestance (5/5 mg/d). Prestance therapy started three-four weeks after CABG and lasted for four months. All participants underwent 24-hour monitoring of ECG and blood pressure (BP), Doppler echocardiography, and Doppler ultrasound of brachial and common carotid arteries. Results. Compared to the CG, the MG demonstrated decreased incidence of pain and painless ischemia episodes, reduced maximal ST segment depression and its total duration, and increased rate threshold of myocardial ischemia. In addition, Prestance therapy was associated with improved systolic and diastolic heart function and significantly improved endothelium-dependent vasodilatation. In patients with normal BP, Prestance (5/5 mg/d) did not cause hypotension, but reduced excessive BP variability. In the MG, acute coronary syndrome (ACS) was registered in 1 individual (3,3 %), while in the CG, it was registered in 4 patients (11.4 %), and in 3 cases, coronary artery stenting was performed. Conclusion. In patients with normal BP, Prestance (5/5 mg/d) therapy in the early post-CABG period had a pronounced anti-ischemic, cardio- and vasoprotective effects, and also prevented excessive BP variability.

Publisher

Silicea - Poligraf, LLC

Subject

Cardiology and Cardiovascular Medicine

Reference25 articles.

1. Dobrovol'skii A.V. Mesto proizvodnykh digidropiridina v lechenii zabolevanii serdechno-sosudistoi sistemy (sovremennoe sostoyanie problemy). RMZh 2008; 16(11): 1599-608.

2. Karpov Yu.A. Optimal'noe lechenie arterial'noi gipertonii i ishemicheskoi bolezni serdtsa: argumenty v pol'zu kombinatsii perindoprila arginina i amlodipina. Cons Med 2010; 5: 51-6.

3. Klyuzhev V.M., Ardashev V.N., Bryukhovetskii A.G., Mikheev A.A. Ishemicheskaya bolezn' serdtsa. M.: Meditsina 2004; 202-29.

4. Rossiiskie natsional'nye rekomendatsii po diagnostike i lecheniyu arterial'noi gipertenzii. Sist gipert 2010; 3: 5-26.

5. Shevchenko Yu.L., Viller A.G., Belevitin A.B. i dr. Osobennosti krovosnabzheniya miokarda posle aortokoronarnogo shuntirovaniya v rannem posleoperatsionnom periode. — V kn.: Tezisy dokladov IV Vserossiiskogo s\"ezda serdechno-sosudistykh khirurgov. M. 1998; 71.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3